ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
14.48
+0.19 (1.33%)
Oct 24, 2024, 4:00 PM EDT - Market closed
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for ACAD stock have an average target of 26.44, with a low estimate of 19 and a high estimate of 39. The average target predicts an increase of 82.60% from the current stock price of 14.48.
Analyst Consensus: Buy
* Price targets were last updated on Aug 8, 2024.
Analyst Ratings
The average analyst rating for ACAD stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 7 | 8 | 8 | 7 | 7 | 6 |
| Hold | 5 | 5 | 5 | 6 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 19 | 19 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 10, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $30 → $23 | Strong Buy | Maintains | $30 → $23 | +58.84% | Aug 8, 2024 |
| UBS | UBS | Strong Buy Maintains $25 → $23 | Strong Buy | Maintains | $25 → $23 | +58.84% | Aug 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +86.46% | Aug 8, 2024 |
| Needham | Needham | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +93.37% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
971.16M
from 726.44M
Increased by 33.69%
Revenue Next Year
1.08B
from 971.16M
Increased by 11.41%
EPS This Year
0.53
from -0.37
EPS Next Year
0.85
from 0.53
Increased by 59.52%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.0B | 1.2B | 1.4B | ||
| Avg | 971.2M | 1.1B | 1.2B | ||
| Low | 910.4M | 982.9M | 1.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 39.3% | 22.9% | 30.6% | ||
| Avg | 33.7% | 11.4% | 11.3% | ||
| Low | 25.3% | 1.2% | -4.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.79 | 1.55 | 2.33 | ||
| Avg | 0.53 | 0.85 | 1.25 | ||
| Low | 0.30 | 0.20 | 0.49 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 192.4% | 175.0% | ||
| Avg | - | 59.5% | 47.7% | ||
| Low | - | -63.1% | -42.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.